E-cigarette use prevalence and the need to develop treatments: What we know and how treatments may help public health

Dr Toll’s presentation will focus on the rise of e-cigarettes as the dominant form of tobacco use in the United States (US) and the need for the development of treatments focusing on e-cigarette reduction and cessation. The supremacy of e-cigarette use by US youths will be briefly discussed, along with data showing that the majority of young adults who use nicotine in the US use e-cigarettes. Preliminary data on nicotine pouch use in US-based youths and adults who use cigarettes, e-cigarettes, and smokeless tobacco will be presented. The US perspective on e-cigarette use will be presented, including views and behaviors regarding adolescent, young adult, and adult use. The relatively cautious stance of the US FDA will be discussed. Data will be presented from multiple pilot studies regarding treatment of adult e-cigarette mono-users and e-cigarette and combusted cigarette dual users, including treatment with varenicline tartrate (for mono-users) and nicotine replacement therapy (for dual users). Very preliminary data on the biological impacts of vaping cessation will be presented.